Drug combinations may enable clinical application by reducing individual drug concentrations for inhibiting EBOV infection. 795 pairs of three-drug combinations of FDA-approved drugs were screened for anti-Ebola virus activity. Two sets of clinical useful three-drug combinations were validated for inhibition of live Ebola virus infection. Mechanisms of action of these drugs were identified in affecting host-pathogen interactions.